NCT04759339View on ClinicalTrials.gov

An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

February 25, 2021

Study Completion Date

February 25, 2021

Conditions
Healthy
Interventions
DRUG

AG-920

AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

American Genomics, LLC

INDUSTRY

NCT04759339 - An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920 | Biotech Hunter | Biotech Hunter